#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you – page 22

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 955
countries: 28
conditions: 2 101

3 955 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Endometrial cancer

Not yet recruiting

Registered drugNo placebo

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:GSK5733584

Contact Research Centre

Ovarian cancer

Not yet recruiting

Registered drugNo placebo

A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Ovarian cancer recurrent

Not yet recruiting

Registered drugNo placebo

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Plasma cell myeloma

Not yet recruiting

Registered drugNo placebo

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Colon cancer+3

Not yet recruiting

Registered drugNo placebo

Effect of a multidisciplinary care pathway on safety of oral anticancer therapy in patients aged ≥70 with cancer (capecitabine and drug combination)

Registered drugNo placebo

France

Participants:65+ years
Substances:Abemaciclib

Contact Research Centre

Chronic graft versus host disease

Not yet recruiting

Registered drugNo placebo

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Diffuse large B-cell lymphoma

Not yet recruiting

Registered drugNo placebo

Phase II study of fixed‑dose, accelerated ramp‑up epcoritamab plus lenalidomide in patients with relapsed/refractory large B‑cell lymphoma after CAR‑T therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Epcoritamab

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Registered drugNo placebo

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Invasive lobular breast carcinoma+1

Not yet recruiting

InvestigationalNo placebo

Diagnostic Accuracy of [68Ga]FAPI-46 PET/CT for Detecting Metastatic Lesions in Patients with Invasive Lobular Breast Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Contact Research Centre

Malignant peritoneal neoplasm+2

Not yet recruiting

Registered drugNo placebo

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azenosertib

Contact Research Centre

Breast cancer

Not yet recruiting

Registered drugNo placebo

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Camizestrant

Contact Research Centre

Systemic lupus erythematosus

Not yet recruiting

Registered drugNo placebo

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.